<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400569</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-14902</org_study_id>
    <secondary_id>GA618075</secondary_id>
    <nct_id>NCT00400569</nct_id>
  </id_info>
  <brief_title>Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma</brief_title>
  <official_title>Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label single site Phase II clinical trial to identify a potentially promising
      therapy dose for Sunitinib malate. The study drug will be taken orally once daily on days 1
      through 28 of each 42 day cycle. Treatment will be continued until there is either disease
      progression or cumulative/acute toxicity.

      All patients with unresectable or metastatic soft tissue sarcoma (STS): leiomyosarcoma,
      liposarcoma, fibrosarcoma, and malignant fibrous histiocytoma (MFH) seen at the Moffitt
      Cancer Center will be screened for eligibility to be enrolled in the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label single site Phase II clinical trial to identify a potentially promising
      therapy dose for Sunitinib malate, an oral multi-kinase inhibitor. The study drug will be
      taken orally once daily on days 1 through 28 of each 42 day cycle. Treatment will be
      continued until there is either disease progression or cumulative/acute toxicity which in the
      opinion of the treating physician or the trial Principal Investigator (PI) compromises the
      ability of the patient to receive treatment or the patient desires to stop treatment.

      All patients with unresectable or metastatic STS: leiomyosarcoma, liposarcoma, fibrosarcoma,
      and MFH seen at the Moffitt Cancer Center will be screened for eligibility to be enrolled in
      the study.

      An office visit will be required before the beginning of every cycle every 6 weeks to assess
      toxicity and for physical examination. Complete blood count (CBC) and differential,
      comprehensive metabolic panel, and electrocardiogram (ECG) will be obtained at every
      scheduled visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Overall Response (OR)</measure>
    <time_frame>From On Treatment to Off Study - average of 6 months</time_frame>
    <description>Objective Radiographic Response Rate. Response assessments were based on the longest diameter tumor measurements in accordance with Response Evaluation Criteria in Solid Tumors (RECIST).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants' Progression Free Survival (PFS)</measure>
    <time_frame>From On Treatment to Off Study - average of 6 months</time_frame>
    <description>Time to tumor progression defined as the duration of time from start of treatment to time of progression. Response assessments were based on the longest diameter tumor measurements in accordance with Response Evaluation Criteria in Solid Tumors (RECIST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants' Overall Survival (OS)</measure>
    <time_frame>From On Treatment to Off Study - average of 6 months</time_frame>
    <description>The median OS times (months) for liposarcoma, leiomyosarcoma and MFH.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>4 years, 7 months</time_frame>
    <description>Determine the number of participants who experience Serious Adverse events while on sunitinib malate study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Liposarcoma</condition>
  <condition>Leiomyosarcoma</condition>
  <condition>Fibrosarcoma</condition>
  <condition>Malignant Fibrous Histiocytoma</condition>
  <arm_group>
    <arm_group_label>Sunitinib Malate (SU011248) Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib Malate (SU011248)</intervention_name>
    <description>For each 6 week cycle, patients will take SU011248 every day in the morning for 4 weeks followed by a 2 week rest period.</description>
    <arm_group_label>Sunitinib Malate (SU011248) Treatment</arm_group_label>
    <other_name>Sutent</other_name>
    <other_name>SU011248</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resolution of all acute toxic effects of prior chemotherapy or radiotherapy or
             surgical procedures to National Cancer Institute (NCI) Common Terminology Criteria for
             Adverse Events (CTCAE) Version 3.0 grade less than or equal to 1.

          -  Adequate organ function as defined by the following criteria:

               -  Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) less than
                  or equal to 2.5 x local laboratory upper limit of normal (ULN), or AST and ALT
                  less than or equal to 5 x ULN if liver function abnormalities are due to
                  underlying malignancy

               -  Total serum bilirubin less than or equal to 1.5 x ULN

               -  Absolute neutrophil count (ANC) greater than or equal to1500/microL

               -  Platelets greater than or equal to 100,000/microL

               -  Hemoglobin greater than or equal to 9.0 g/dL

               -  Serum calcium less than or equal to 12.0 mg/dL

               -  Serum creatinine less than or equal to 1.5 x ULN

          -  Histologically-proven liposarcoma, leiomyosarcoma, fibrosarcoma, or MFH

          -  Measurable disease radiographically

          -  Disease that is deemed surgically unresectable and/or metastatic

          -  Age greater than or equal to 18 years

          -  Life expectancy greater than 16 weeks

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2

          -  Patients may have had up to 3 prior chemotherapies within 4 weeks of starting the
             study treatment.

        Exclusion Criteria:

          -  Major surgery or radiation therapy or chemotherapy within 4 weeks of starting the
             study treatment.

          -  NCI CTCAE version 3 grade 3 hemorrhage within 4 weeks of starting the study treatment.

          -  History of or known brain metastases, spinal cord compression, or carcinomatous
             meningitis, or evidence of symptomatic brain or leptomeningeal disease.

          -  Any of the following within the 6 months prior to study drug administration:

               -  myocardial infarction,

               -  severe/unstable angina,

               -  coronary/peripheral artery bypass graft,

               -  symptomatic congestive heart failure,

               -  cerebrovascular accident or transient ischemic attack, or pulmonary embolism

          -  Ongoing cardiac dysrhythmias of NCI CTCAE greater than or equal to grade 2

          -  Prolonged QTc interval on baseline electrocardiogram (ECG) &gt; 500 msec.

          -  Hypertension that cannot be controlled by medications (&gt;150/100 mm Hg despite optimal
             medical therapy)

          -  Prior tyrosine kinase inhibitor therapy

          -  Pre-existing thyroid abnormality with thyroid function that cannot be maintained in
             the normal range with medication

          -  Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome
             (AIDS)-related illness or other active infection

          -  Concurrent treatment on another clinical trial, except supportive care or
             non-treatment trials

          -  Concomitant use of agents known to induce or inhibit CYP3A4

          -  Concomitant use of agents metabolized by the cytochrome P450 system

          -  Ongoing treatment with therapeutic doses of Coumadin (low dose Coumadin up to 2 mg by
             mouth [PO] daily for thrombo-prophylaxis is allowed)

          -  Pregnancy or breastfeeding patients

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or study
             drug administration, or may interfere with the interpretation of study results, and in
             the judgment of the investigator would make the subject inappropriate for entry into
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Chiappori, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/</url>
    <description>Moffitt Cancer Center Clinical Trials Website</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2006</study_first_submitted>
  <study_first_submitted_qc>November 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2006</study_first_posted>
  <results_first_submitted>July 25, 2012</results_first_submitted>
  <results_first_submitted_qc>July 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 28, 2012</results_first_posted>
  <last_update_submitted>July 25, 2012</last_update_submitted>
  <last_update_submitted_qc>July 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sunitinib malate</keyword>
  <keyword>SUTENT</keyword>
  <keyword>SU011248</keyword>
  <keyword>Soft tissue sarcoma</keyword>
  <keyword>Gastrointestinal stromal tumors (GIST)</keyword>
  <keyword>MFH</keyword>
  <keyword>Tyrosine kinase inhibitor</keyword>
  <keyword>Imatinib mesylate</keyword>
  <keyword>Phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Liposarcoma</mesh_term>
    <mesh_term>Fibrosarcoma</mesh_term>
    <mesh_term>Histiocytoma</mesh_term>
    <mesh_term>Histiocytoma, Benign Fibrous</mesh_term>
    <mesh_term>Histiocytoma, Malignant Fibrous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From September 2006 to August 2007, a total of 48 patients were enrolled on the study by the Moffitt Cancer Center Sarcoma Program. In general, the patients had been heavily pretreated previously, with a significant number receiving more than one prior chemotherapy regimen and most with multiple metastatic sites.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Experimental: Sunitinib Malate (SU011248) Treatment</title>
          <description>Sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental: Sunitinib Malate (SU011248) Treatment</title>
          <description>Sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Overall Response (OR)</title>
        <description>Objective Radiographic Response Rate. Response assessments were based on the longest diameter tumor measurements in accordance with Response Evaluation Criteria in Solid Tumors (RECIST).</description>
        <time_frame>From On Treatment to Off Study - average of 6 months</time_frame>
        <population>All participants assessable for response</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Sunitinib Malate (SU011248) Treatment</title>
            <description>Sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Response (OR)</title>
          <description>Objective Radiographic Response Rate. Response assessments were based on the longest diameter tumor measurements in accordance with Response Evaluation Criteria in Solid Tumors (RECIST).</description>
          <population>All participants assessable for response</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants' Progression Free Survival (PFS)</title>
        <description>Time to tumor progression defined as the duration of time from start of treatment to time of progression. Response assessments were based on the longest diameter tumor measurements in accordance with Response Evaluation Criteria in Solid Tumors (RECIST).</description>
        <time_frame>From On Treatment to Off Study - average of 6 months</time_frame>
        <population>All participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Liposarcoma Cohort Only</title>
            <description>Experimental: Sunitinib Malate (SU011248) Treatment</description>
          </group>
          <group group_id="O2">
            <title>Leiomyosarcoma Cohort Only</title>
            <description>Experimental: Sunitinib Malate (SU011248) Treatment</description>
          </group>
          <group group_id="O3">
            <title>Malignant Fibrous Histiocytoma (MFH) Cohort Only</title>
            <description>Experimental: Sunitinib Malate (SU011248) Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Participants' Progression Free Survival (PFS)</title>
          <description>Time to tumor progression defined as the duration of time from start of treatment to time of progression. Response assessments were based on the longest diameter tumor measurements in accordance with Response Evaluation Criteria in Solid Tumors (RECIST).</description>
          <population>All participants who completed the study</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="2.8" upper_limit="4.4"/>
                    <measurement group_id="O2" value="4.2" lower_limit="2.0" upper_limit="8.3"/>
                    <measurement group_id="O3" value="2.5" lower_limit="1.4" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants' Overall Survival (OS)</title>
        <description>The median OS times (months) for liposarcoma, leiomyosarcoma and MFH.</description>
        <time_frame>From On Treatment to Off Study - average of 6 months</time_frame>
        <population>All participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Liposarcoma Cohort Only</title>
            <description>Experimental: Sunitinib Malate (SU011248) Treatment</description>
          </group>
          <group group_id="O2">
            <title>Leiomyosarcoma Cohort Only</title>
            <description>Experimental: Sunitinib Malate (SU011248) Treatment</description>
          </group>
          <group group_id="O3">
            <title>Malignant Fibrous Histiocytoma (MFH) Cohort Only</title>
            <description>Experimental: Sunitinib Malate (SU011248) Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Participants' Overall Survival (OS)</title>
          <description>The median OS times (months) for liposarcoma, leiomyosarcoma and MFH.</description>
          <population>All participants who completed the study</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="5.2" upper_limit="27.7"/>
                    <measurement group_id="O2" value="10.1" lower_limit="4.1" upper_limit="11.9"/>
                    <measurement group_id="O3" value="13.6" lower_limit="3.1" upper_limit="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs)</title>
        <description>Determine the number of participants who experience Serious Adverse events while on sunitinib malate study.</description>
        <time_frame>4 years, 7 months</time_frame>
        <population>All Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Sunitinib Malate (SU011248) Treatment</title>
            <description>Sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs)</title>
          <description>Determine the number of participants who experience Serious Adverse events while on sunitinib malate study.</description>
          <population>All Participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years, 7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Experimental: Sunitinib Malate (SU011248) Treatment</title>
          <description>Sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC V3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac general</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Abdomen</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term - Disease progression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hemorrhate/Bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver dysfunction/failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with unknown ANC - Peritoneal cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC V3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="20" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="14" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="22" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dysguesia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="18" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="44" subjects_affected="30" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hemorrhage/bleeding</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="27" subjects_affected="15" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was amended to exclude fibrosarcoma after only one patient was accrued while the other cohorts had completed 75% or more of their planned accrual. Only patients with liposarcoma, leiomyosarcoma, or MFH were enrolled after this amendment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alberto Chiappori, M.D.</name_or_title>
      <organization>H. Lee Moffitt Cancer Center and Research Institute</organization>
      <phone>813-745-2158</phone>
      <email>alberto.chiappori@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

